Toxikon Corp. has completed toxicity studies in two species for Cellceutix Corp.’s Kevetrin, a compound in development for the treatment of resistant lung and breast cancers. Toxikon also performed safety pharmacology studies of Kevetrin in the central nervous system and the cardiovascular and respiratory systems. The tox studies, required for an IND filing, are designed to confirm that Kevetrin meets FDA safety requirements for clinical studies in humans. In animal studies, Kevetrin was foun...